Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies targeting breast cancer and other HER2/neu-expressing cancers. Its lead product candidate, GP2, is a nine-amino acid peptide derived from the HER2/neu protein, combined with GM-CSF to form GLSI-100, designed to prevent breast cancer recurrences in patients who have undergone surgery and standard treatments like trastuzumab. The company is advancing GLSI-100 through the Flamingo-01 Phase III clinical trial, a global, randomized, double-blinded study enrolling up to 750 high-risk HER2-positive patients across approximately 150 sites in the United States and Europe, in collaboration with leading oncology networks and institutions. This immunotherapy aims to activate the immune system against HER2/neu-expressing tumor cells, addressing an unmet need in preventing recurrence for patients where existing therapies fall short. Founded in 2006 and headquartered in Stafford, Texas, Greenwich LifeSciences Inc. operates in the biotechnology sector, emphasizing peptide-based vaccines for oncology applications.